We welcome you to this year's SNMMI Annual Meeting. We look forward to meeting our current and potential partners.
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
ImaginAb’s vision is to transform patient care, and help people live better and healthier lives. For more information visit www.imaginab.com